Eli Lilly and Company (LLY)
| Market Cap | 741.90B |
| Revenue (ttm) | 53.26B |
| Net Income (ttm) | 13.80B |
| Shares Out | 897.74M |
| EPS (ttm) | 15.29 |
| PE Ratio | 54.04 |
| Forward PE | 30.35 |
| Dividend | $6.00 (0.73%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 2,114,752 |
| Open | 825.00 |
| Previous Close | 825.45 |
| Day's Range | 811.48 - 826.42 |
| 52-Week Range | 623.78 - 935.63 |
| Beta | 0.46 |
| Analysts | Strong Buy |
| Price Target | 969.56 (+17.32%) |
| Earnings Date | Oct 30, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $969.56, which is an increase of 17.32% from the latest price.
News
Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis
Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing the previous two-injection regimen Omvoh single-injection dosing will be available for U.S. patient...
Lilly declares fourth-quarter 2025 dividend
INDIANAPOLIS , Oct. 27, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common...
Baron Health Care Fund Q3 2025 Top Contributors And Detractors
Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagno...
LLY Stock To $1,100?
Eli Lilly (LLY) shares have surged by 16% over the last month and are currently priced at $825. U.S. pharmaceutical stocks have done well of late, as large drugmakers such as Pfizer and AstraZeneca si...
Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis
Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool deferral time — reflecting the spectrum of its burde...
Eli Lilly: Is Another Monster Quarter Coming
October 30th is the day when Eli Lilly will report its third-quarter results, including sales of its 'superstars' Zepbound and Mounjaro. Since my article was published on September 8, Eli Lilly's stoc...
Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Adver...
Eli Lilly to buy gene therapy developer Adverum in about $262 million deal
Eli Lilly said on Friday it would acquire gene therapy developer Adverum Biotechnologies in a deal valued at up to $261.7 million, aiming to strengthen its pipeline with an experimental eye disease tr...
Eli Lilly: Time To Buy LLY Stock?
Eli Lilly stock (NYSE: LLY) is up 10% this month, a rise driven by strong clinical trial progress. This includes the announcement of positive Phase 3 results in October 2025 for its oral GLP-1 drug, o...
Lilly to Acquire Adverum Biotechnologies
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Acquisition aligns Lilly'...
Mounjaro Maker Eli Lilly Jumps In Quality Despite Trump-Fueled Price Cut Fears
Eli Lilly and Co. (NYSE:LLY) has surged into the top decile of quality rankings among S&P 500 peers, achieving a percentile score of 90.25 on the latest composite quality report, despite fresh uncerta...
Eli Lilly reports promising data for alopecia and eczema drugs, eyes label expansion
Eli Lilly announced on Friday safety and efficacy results from two separate late-stage studies testing its approved drugs for alopecia and eczema.
Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often underrepresented in clinical trials New data show ...
Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis
New long-term extension data show approximately 80% of patients achieved or maintained meaningful skin improvement (EASI 75) with EBGLYSS with half the doses compared to approved monthly maintenance d...
Eli Lilly Accelerates On Obesity Data While Novo Nordisk Retreats
Eli Lilly is a Strong Buy, driven by exceptional growth in obesity and diabetes drugs Mounjaro and Zepbound, plus pipeline innovation. LLY's diversified business mix, global reach, and proactive U.S. ...
Eli Lilly allows Cipla to sell weight loss drug under new brand in India
Eli Lilly signed an agreement with Cipla , allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a separate brand in the country, the companies said on Thursday.
Our Top 10 High Growth Dividend Stocks - October 2025
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...
President Trump targets $150 MFN price for GLP-1s
Shares of Eli Lilly and Novo Nordisk came under pressure after President Trump said during an event at the White House that the administration is looking bring down prices of popular weight loss GLP-1...
Eli Lilly and Novo Nordisk stocks fall as Trump says he wants $150 price for GLP-1s
Shares of Eli Lilly and Novo Nordisk dropped Friday, after President Donald Trump said his administration aims to cut the cost of brand name GLP-1 weight loss drugs to $150 per month, a fraction of th...
3 Price Catalysts For Eli Lilly
Eli Lilly (NYSE:LLY) is up by ~30% since I last checked on it in August, with further upside potential remaining. Three potential developments can catalyse the stock further to achieve this upside, or...
Here's What Trump Said That's Pressuring Novo Nordisk and Eli Lilly Stocks
Novo Nordisk (NVO) and Eli Lilly (LLY) shares slumped in early trading Friday after President Trump promised to lower the prices of popular weight-loss drugs, such as Novo Nordisk's Ozempic and Eli Li...
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to...
Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer Seven-year results from the P...

